Oligo Fucoidan

DIETARY_SUPPLEMENT4 trials

Sponsors

Hi-Q Marine Biotech International, Ltd., Taipei Medical University, Department of Nutrition, Hungkuang University

Conditions

Advanced Hepatocellular CarcinomaNSCLC Stage IVNSCLC, Stage IIIUterine Leiomyomapatients with NSCLC non-small cell lung cancer, oligo-fucoidan, survival rate, quality of life, immunity

Early Phase 1

Oral administration of oligo fucoidan improves the survival rate, quality of life, and immunity in patients with lung cancer

Active, not recruitingTCTR20231018001

Department of Nutrition, Hungkuang Universitypatients with NSCLC non-small cell lung cancer, oligo-fucoidan, survival rate, quality of life, immunity

Start: 2019-08-21Target: 20Updated: 2026-08-03

Effects of Oligo-fucoidan on Leiomyoma Patients

CompletedNCT06959966

Taipei Medical UniversityUterine Leiomyoma

Start: 2019-08-14End: 2023-01-31Updated: 2025-05-07

Unknown Phase

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

WithdrawnNCT03130829

Hi-Q Marine Biotech International, Ltd.NSCLC, Stage III, NSCLC Stage IV

Start: 2017-04-26End: 2020-04-30Updated: 2019-08-28

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

TerminatedNCT04066660

Hi-Q Marine Biotech International, Ltd.Advanced Hepatocellular Carcinoma

Start: 2019-10-01End: 2024-07-31Updated: 2025-01-13